Phase Ⅲ Randomized Trial in Postoperative Hepatocellular Carcinoma
Status:
Completed
Trial end date:
2005-07-01
Target enrollment:
Participant gender:
Summary
* OBJECTIVES
1. To investigate whether adjuvant IFN-α therapy can delay or reduce the 2-5 years
recurrence rate in curatively resected HCC .
2. To examine whether adjuvant IFN-α therapy can prolong the disease-free survival in
curatively resected HCC.
3. To determine the safety and tolerance of adjuvant IFN-α therapy in postoperative HCC
with or without cirrhosis.
4. To investigate the change of activity of HBV and HCV in postoperative HCC patients with
adjuvant IFN-α therapy.
5. To correlate the changes of viral status with the clinical outcome in post-operative HCC
patients with adjuvant IFN-α therapy.
Phase:
Phase 3
Details
Lead Sponsor:
National Health Research Institutes, Taiwan
Collaborators:
Chang Gung Memorial Hospital China Medical University Hospital Mackay Memorial Hospital National Taiwan University Hospital Taipei Veterans General Hospital, Taiwan Tri-Service General Hospital